Does thyroid hormone support hepatic LDL receptor expression and cholesterol turnover?

Thyroid hormones serve as primary metabolic regulators of lipid homeostasis, directly modulating how the liver processes, clears, and excretes circulating low-density lipoprotein (LDL) cholesterol.

Mechanistic pathways

• Direct Genomic Activation: Active thyroid hormone (T3) binds to hepatic thyroid hormone receptors (primarily TRβ), directly activating thyroid hormone response elements (TREs) on the LDL receptor (LDLR) promoter to initiate rapid transcription.
• SREBP-2 and PCSK9 Modulation: T3 transcriptionally upregulates SREBP-2 expression, which binds to sterol regulatory elements (SREs) to further drive LDLR expression. Concurrently, T3 downregulates circulating PCSK9 levels, preventing post-translational degradation of LDLR and increasing receptor abundance on the hepatocyte surface.
• Cholesterol Turnover: T3 accelerates systemic cholesterol disposal by inducing the transcription of cholesterol 7α-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis, by suppressing small heterodimer partner (SHP) expression via LRH-1 interference.

Clinical evidence

• Atherogenic LDL Retention: A state of low free T3 coupled with higher TSH diminishes hepatic LDLR expression and activity. This impairs the liver's capacity to clear low-density lipoproteins, leading to prolonged LDL retention.
• Hypothyroidism Thresholds: This pathway manifests clinically as elevated odds of hypercholesterolemia in subclinical hypothyroidism, with the most pronounced elevations in total cholesterol and LDL-C occurring when TSH levels exceed 10 mIU/L.
• Intervention Outcomes: Restoring thyroid hormone action with levothyroxine therapy reverses these lipid abnormalities, resulting in statistically significant reductions in circulating LDL-C (averaging 8–12 mg/dL) and total cholesterol, alongside a lower overall circulating atherogenic particle burden (Apolipoprotein B) in older cohorts.

Bottom line

• A state of low free T3 and elevated TSH directly impairs hepatic LDLR expression and CYP7A1-mediated cholesterol turnover, resulting in systemic LDL retention. Normalizing thyroid function restores receptor-mediated clearance and significantly reduces circulating atherogenic lipid levels.